Corporate Presentation

July 2023

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may",

"will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These

statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

2

Poxel's Mission & Key Investment Highlights

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC INFLAMMATION

DISORDERS

(cellular energy

homeostasisTISSUE

imbalances) DEGENERATION & CELL DEATH

apoptosis,

necrosis

Strategic focus on rare metabolic diseases and NASH

Royalties from TWYMEEG® (Imeglimin), approved and launched in Japan in 2021 for Type 2 Diabetes

Proven capabilities to build solid partnerships and to lead drug development

Highly Experienced Management Team in

Metabolic Diseases

3

Key Financial & Shareholder Information

Market data

Shareholder ownership1

Bpi France

14.4%

Ticker: POXEL

ISIN: FR0012432516

Number of shares: 34 252 6461

Key financials

  • As of 3/31/23 cash & cash equivalents:
    EUR 10.6 million

Founders

8.8%

Floating

76.8%

Analyst coverage

Bryan Garnier

Alex Cogut

Degroof Petercam

David Seynnaeve

Jefferies

Lucy Codrington

JMP Securities

Jason Butler

4 1. As of June 30, 2023. For the most up to date share count, please refer to the website: Regulatory Documentation | Poxel SA (poxelpharma.com)

Leadership Team

Highly Experienced Management Team; Extensive R&D and Metabolic Expertise

Pascale Fouqueray (MD, PhD)

Thomas Kuhn (Pharm D,

EVP, Clinical Development &

MBA)

Regulatory Affairs,

Chief Executive Officer and

Co-founder

Co-founder

Sébastien Bolze (Pharm D,

PhD)

EVP, Chief Operating Officer

(COO), Co-founder

Sylvie Bertrand

Sophie Bozec (PhD)

Vice President, Human

SVP, R&D Pharmacology &

Resources

Scientific Communication,

Co-founder

Quentin Durand

EVP, Chief Legal Officer and

Head of CSR Corporate

Social Responsibility

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Poxel SA published this content on 18 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2023 21:44:00 UTC.